Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of CD137L in preparation of medicine for treating non-small cell lung cancer

A non-small cell lung cancer, 1. CD137L technology, applied in the application field of CD137L in the preparation of drugs for the treatment of non-small cell lung cancer, can solve the problems such as no reports of the role of CD137L in non-small cell lung cancer, and achieve huge application prospects and markets value effect

Inactive Publication Date: 2012-07-25
JIANGSU PROVINCE HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] But there is no report on the role of CD137L in the treatment of non-small cell lung cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CD137L in preparation of medicine for treating non-small cell lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] 1. Cloning and identification of CD137L gene:

[0015] Total RNA was extracted from human lung adenocarcinoma A549 cells in logarithmic growth phase, and mRNA was reverse transcribed into cDNA. The primers for cloning the fragment of hCD137L (Genbank accession number GI:209954675) were respectively added restriction sites: Not I and Xho I, and the fragment length was 794 bp. The primer sequence is as follows: Forward 5-ATT CGC GGCCGC A TGG AAT ACG CCT CTG ACG CTT C-3, Reverse 5-GGC CCT CGA GCG CCG CC TTA TTC CGA CCT CGG TGA AGG GA-3, perform PCR reaction; PCR operation process: Pre-denaturation at 94°C for 3 min, denaturation at 94°C for 30 s, annealing / extension at 68°C for 2 min, 30 cycles, and finally extension at 70°C for 3 min. The product fragments of corresponding size were recovered by cutting the gel and purified with a kit.

[0016] 2. Connection, transformation and identification:

[0017] The purified cloning product and plasmid pcDNA3 (purchased from Ta...

Embodiment 2

[0023] The expression of CD137L in non-small cell lung cancer (NSCLC) was detected by immunohistochemical streptavidin-peroxidase method (Streptavidin-perosidase, SP):

[0024] 61 non-small cell lung cancer tissue specimens (61 lung cancer specimens undergoing surgery from the First Affiliated Hospital of Nanjing Medical University from January 2006 to December 2008, identified by the Pathology Department of the First Affiliated Hospital of Nanjing Medical University) were fixed with 10% formaldehyde , Paraffin-embedded, 4μm thick serial sections. Rabbit anti-human CD137L monoclonal antibody was purchased from Epitomics Company, the concentration of monoclonal antibody working solution was 1ug / ml, SP immunohistochemistry kit was purchased from Fuzhou Maixin Biotechnology Development Company, DBA color development, hematoxylin counterstaining, all steps were strictly followed Instructions are carried out. NSCLC tissue samples known to be positive for CD137L were used as a posi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of CD137L in preparation of a medicine for treating non-small cell lung cancer. According to the invention, CD137L capable of treating lung cancer, especially non-small cell lung cancer is proposed for the first time, provides possibility and application for development of related medicines as a medicine-screening target, and has great application prospect and market value.

Description

Technical field: [0001] The invention relates to the application of CD137L in the preparation of medicines for treating non-small cell lung cancer. Background technique: [0002] Costimulatory molecules play an extremely important role in regulating immune responses. The co-stimulatory signal was first proposed and confirmed by Brestcher and Cohn in 1970 on the basis of the double-signal theory of T cell activation. Unsensitized T cells get antigen signals (first signals) through the "antigen peptide-MHC-TCR" triplet Finally, co-stimulatory molecules are required to provide an activation signal (second signal) to activate, and the second signal is called co-stimulatory signal. According to the structure, costimulatory molecules can be divided into two categories: (1) Tumor necrosis factor (TNF) - tumor necrosis factor receptor (TNFR) superfamily, including CD27 ligand (Ligand) (CD27L) - CD27, CD30L - CD30, CD40L-CD40, OX40L-OX40, CD137L-CD137, FasL-Fas, etc.; (2) Immunoglo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61P35/00
Inventor 束永前郭人花殷咏梅武常玲承婷
Owner JIANGSU PROVINCE HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com